Prothena Reports Q4 2025 Results as Neurodegeneration Pipeline Advances with Major Partnerships
核心洞察
Prothena reported Q4 2025 adjusted loss of 45 cents per share, meeting estimates, while revenues totaled $0.02 million, missing consensus expectations of $3.0 million.
The company's neurodegeneration pipeline continues advancing with three late-stage programs: prasinezumab for Parkinson's disease (搜索) with Roche, coramitug for ATTR-CM with Novo Nordisk, and BMS-986446 for Alzheimer's disease (搜索) with Bristol Myers Squibb (搜索).
Prothena expects up to $105 million in clinical milestone payments in 2026 from partners, with potential milestones tied to enrollment criteria in ongoing Phase 3 studies.
Prothena Corporation (搜索) reported fourth-quarter 2025 adjusted loss per share of 45 cents, meeting analyst estimates, as the biotechnology company advances its neurodegeneration pipeline through major pharmaceutical partnerships. The Dublin-based company posted revenues of $0.02 million for the quarter, falling short of the $3.0 million consensus estimate.
The company's financial performance reflects its transition from internal development to a partnership-focused strategy, with three late-stage programs now being advanced by major pharmaceutical companies. Research and development expenses plunged 71% year-over-year to $14.6 million in Q4, driven by reduced clinical trial, manufacturing, personnel and consulting costs.
Late-Stage Pipeline Advances Through Strategic Partnerships
Prothena's most advanced asset, prasinezumab, is being evaluated by Roche in the ongoing Phase 3 PARAISO clinical trial for early-stage Parkinson's disease (搜索). The study involves approximately 900 participants with primary completion expected in 2029. Roche has stated that prasinezumab has peak sales potential greater than $3.5 billion and could represent the first disease-modifying treatment for a condition affecting 10 million people worldwide.
Novo Nordisk is advancing coramitug (formerly PRX004), a potential first-in-class amyloid depleter antibody for ATTR amyloidosis (搜索) with cardiomyopathy (ATTR-CM). The Phase 3 CLEOPATTRA clinical trial includes approximately 1,280 participants with primary completion expected in 2029. Novo Nordisk presented Phase 2 results during a late-breaking session at the American Heart Association Scientific Sessions in November 2025, with the data supporting the ongoing Phase 3 study.
Bristol Myers Squibb (搜索) is conducting the Phase 2 TargetTau-1 clinical trial for BMS-986446 (formerly PRX005) in approximately 310 patients with early Alzheimer's disease (搜索), with primary completion expected in the first half of 2027. The antibody specifically targets a key epitope within the microtubule binding region of tau (搜索) protein and has received Fast Track designation from the FDA.
Milestone Payments and Financial Outlook
Prothena expects to earn up to $105 million in aggregate clinical milestone payments from strategic partners in 2026. The company anticipates earning a clinical milestone in the first half of 2026 when prespecified enrollment criteria are met in Novo Nordisk's ongoing Phase 3 study. Additionally, Prothena expects to earn a milestone payment by the end of 2026 if Bristol Myers Squibb (搜索) decides to further develop PRX019.
For 2026, the company projects net cash burn from operating and investing activities of $50-55 million and expects to end the year with approximately $255 million in cash, cash equivalents, and restricted cash. The estimated net loss for 2026 is projected to be $67-72 million, which includes an estimated $24 million of non-cash share-based compensation expense.
Emerging Technologies and Preclinical Programs
Prothena is developing its proprietary CYTOPE technology to target intracellular disease pathways. The company's TDP-43 CYTOPE program enables precision intracellular targeting of TDP-43 pathology, a defining pathogenic feature of ALS (搜索) and other TDP-43 proteinopathies. Preclinical data was presented at Neuroscience 2025 and the International Symposium of ALS/MND, demonstrating the potential of the CYTOPE technology in multiple preclinical models.
The company is also advancing PRX012-TfR, combining its wholly-owned PRX012 antibody with transferrin receptor technology. Phase 1 ASCENT clinical program preliminary results showed that patients on the 400 mg dose level for 18 months reached a mean centiloid level of approximately 16.0, with 9 of 12 patients achieving amyloid negativity. However, the robust plaque clearance was associated with non-competitive rates of ARIA-E, leading Prothena to explore the transferrin receptor approach in preclinical studies.
As of December 31, 2025, Prothena maintained $308.4 million in cash, cash equivalents and restricted cash with no debt. The company's shares have declined 42% over the past year, contrasting with the industry's 18.8% growth during the same period.